The Octopus Value Investing

The Octopus Value Investing

Connect

Featured Posts

Novo NordiskNovo Nordisk
Novo Nordisk Valuation Update

Novo Nordisk Valuation Update

The Margin of Safety Might Have Never Been Larger

The Octopus Value Investing
The Octopus Value Investing
Earnings ReviewEarnings Review
+1+1
Novo Nordisk - Q1 2025 Earnings Review

Novo Nordisk - Q1 2025 Earnings Review

When Expectations Are So Low...

The Octopus Value Investing
The Octopus Value Investing
Novo NordiskNovo Nordisk
Novo Nordisk - H1 2025 Earnings Review

Novo Nordisk - H1 2025 Earnings Review

Lars Fruergaard's Final Earnings as CEO

The Octopus Value Investing
The Octopus Value Investing

Archive

MiscellaneousMiscellaneous
#5 Investment Sidebar Snapshots

#5 Investment Sidebar Snapshots

Reviewing New Data of Novo Nordisk Business, Schott Pharma Preliminary FY25 Results & a New Investment Thesis

The Octopus Value Investing
The Octopus Value Investing
PandoraPandora
Pandora Valuation Update

Pandora Valuation Update

Is Pandora's Stock Price Reflecting its Intrisinc Value?

The Octopus Value Investing
The Octopus Value Investing
PandoraPandora
+1+1
Pandora A/S - Q3 2025 Earnings Review

Pandora A/S - Q3 2025 Earnings Review

The Market Turns Overly Pessimistic on External Headwinds Not Only Affecting Pandora

The Octopus Value Investing
The Octopus Value Investing
Earnings ReviewEarnings Review
+1+1
Novo Nordisk - Q3 2025 Earnings Review

Novo Nordisk - Q3 2025 Earnings Review

Disappointing, Yes. Unexpected, No.

The Octopus Value Investing
The Octopus Value Investing
MiscellaneousMiscellaneous
#4 Investment Sidebar Snapshots

#4 Investment Sidebar Snapshots

September 2025 News & Insights Recap

The Octopus Value Investing
The Octopus Value Investing
Theon InternationalTheon International
Theon International - Quantitative Analysis

Theon International - Quantitative Analysis

Financials just made my conviction grow bigger

The Octopus Value Investing
The Octopus Value Investing
MiscellaneousMiscellaneous
#3 Investment Sidebar Snapshots

#3 Investment Sidebar Snapshots

Monlunabant, Novo Nordisk & Lesson from 10 Years of US Biosimilars Market

The Octopus Value Investing
The Octopus Value Investing
PandoraPandora
+1+1
Pandora A/S - H1 2025 Earnings Review

Pandora A/S - H1 2025 Earnings Review

The Stocks Plunging While the Company is Meeting the FY25 Guidance

The Octopus Value Investing
The Octopus Value Investing
Novo NordiskNovo Nordisk
Novo Nordisk - H1 2025 Earnings Review

Novo Nordisk - H1 2025 Earnings Review

Lars Fruergaard's Final Earnings as CEO

The Octopus Value Investing
The Octopus Value Investing
PandoraPandora
Alexander Lacik, CEO of Pandora, Interview in "Ett Rikare Liv" Podcast

Alexander Lacik, CEO of Pandora, Interview in "Ett Rikare Liv" Podcast

Highlights and Transcripts Translated to English

The Octopus Value Investing
The Octopus Value Investing
The Octopus PortfolioThe Octopus Portfolio
#4 The Journey of Compounding - H1 2025 Letter to Readers

#4 The Journey of Compounding - H1 2025 Letter to Readers

Reflections of a Hectic Semester in the Market

The Octopus Value Investing
The Octopus Value Investing
MiscellaneousMiscellaneous
+1+1
#2 Investment Sidebar Snapshots

#2 Investment Sidebar Snapshots

Compiling One Month of Novo Nordisk News & Updates

The Octopus Value Investing
The Octopus Value Investing
FirstBack
123456
Next Last